Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

  • GBI Research
  • May 2017
  • Pharmaceutical
  • 84 pages

Report Description

1
1

The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma, with lymphomas the most prevalent. Due to a degree of crossover between hematological malignancies in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

The report assesses versatile and first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 477 first-in-class products.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, thanks to the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

The first-in-class targets in the pipeline are numerous and varied. Cytokine signaling targets are the most common, with a total of 548 across all stages of development, followed by kinases. These target categories account for the majority of targeted immunotherapies, which are the primary focus of current development activity within oncology. The other target families have far fewer first-in-class and versatile first-in-class products, reflecting the strong interest and potential versatility of cancer immunotherapies.

Scope

  • With 1,474 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future hematological cancer market?
  • There are 477 first-in-class products in the hematological cancer pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • The majority of first-in-class products were identified to be in development for multiple indications. Are versatile products likely to play a key role in the future treatment of hematological cancer?
  • Analysis of the history of strategic consolidations revealed an increasing amount of deal activity and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy

  • Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available. 
  • Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market. 
  • Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers. 
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail. 
  • Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are being developed for.
  • Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Have query on this report?

Make an Enquiry

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 Large Therapy Area with a High Degree of Pathophysiological Crossover 5
2.2 High Degree of First-in-Class Programs and Program Versatility in a Strong Pipeline 5
2.3 Sharp Increase in Deal Activity in Recent Years 5

3 The Case for Innovation in the Hematological Cancer Market 6
3.1 Growing Number of Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 9
3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Symptoms 10
4.3 Diagnosis 10
4.3.1 Leukemia 10
4.3.2 Lymphoma 11
4.3.3 Myeloma 12
4.4 Etiology 12
4.4.1 Leukemia 12
4.4.2 Lymphoma 12
4.4.3 Myeloma 12
4.5 Pathophysiology 13
4.5.1 Leukemia 13
4.5.2 Lymphoma 14
4.5.3 Myeloma 16
4.6 Epidemiology 17
4.6.1 Leukemia 17
4.6.2 Lymphoma 18
4.6.3 Myeloma 18
4.7 Treatment 18
4.7.1 Surgery and Radiation Therapy 19
4.7.2 Stem-Cell Transplantation 19
4.7.3 Pharmacotherapy 20
4.8 Overview of Marketed Products 21
4.9 Current Unmet Need in the Hematological Cancer Market 22

Table 1: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, Forecast 2017 17
Table 2: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Commonly Used Chemotherapy Regimens, 2017 20
Table 3: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Receptor Neurogenic Locus Notch Homolog Protein 1 as a Molecular Target, 2017 46
Table 4: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR-1 as a Molecular Target, 2017 47
Table 5: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Aurora Kinase-A and -B as a Molecular Target, 2017 49
Table 6: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for TNF Receptor Superfamily Member-6 as a Molecular Target, 2017 51
Table 7: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Leukocyte Surface Antigen CD47 as a Molecular Target, 2017 52
Table 8: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Molecular Target e3 Ubiquitin Protein Ligase MDM2, 2017 54
Table 9: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Transforming Growth Factor-Beta Receptor Type-1 as a Molecular Target, 2017 56
Table 10: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Spleen Tyrosine Kinase as a Molecular Target, 2017 58

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074